VICTORIA, Sept. 23, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), an
industry leader in the discovery of novel, therapeutic antibodies,
announces its AbthenaTM bispecific antibody platform and
the complementary ArtemisTM Intelligence Metadata
(AIM)TM suite.
Bispecific antibodies are a class of engineered antibodies and
antibody-like proteins that, in contrast to traditional,
monospecific antibodies, do not occur naturally.
AbthenaTM bispecifics have the ability to bind two
different molecules with a single antibody, increasing the
therapeutic effectiveness of targeting infectious diseases, payload
delivery and functional activity toward challenging targets.
Alternatively, AbthenaTM products can be used to 'dual
target', allowing detection or binding of a target cell type with
much higher specificity than traditional, monospecific
antibodies.
At ImmunoPrecise, we have designed an advanced discovery
platform for wild-type and fully human bispecific antibody
components, which allows for the generation of heterodimer,
optimized, IgG backbones with validated binding attributes.
AbthenaTM produces yields comparable to its monospecific
equivalents, with a high degree of dimer formation, a platform
which blends seamlessly with Artemis Intelligence Metadata
(AIM)TM capabilities to enable rapid turnaround on
additional algorithmic outputs in therapeutic optimization,
stability, affinity and manufacturability.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an international, full-service, therapeutic
antibody discovery company offering species agnostic advancements
such as the B cell SelectTM single-cell interrogation
technology; DeepDisplayTM, for custom, synthetic DNA
libraries, and the AbthenaTM bispecific program. IPA is
focused on the next generation of antibody discovery, to deliver
the most therapeutically relevant antibodies, in a shorter period
of time, with the highest probability of succeeding to clinical
trials.
ImmunoPrecise discovery and development are conducted in
Utrecht and Oss, the Netherlands (U-Protein Express and IPA
Europe, respectively), and in Victoria,
British Columbia (IPA Canada). The Company operates globally
to offer a continuum of superior antibody services, transforming
the face of therapeutic discovery, by decreasing turnaround time
and risk, and promoting clinical success.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.